JP7850132B2 - ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ - Google Patents

ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ

Info

Publication number
JP7850132B2
JP7850132B2 JP2023504184A JP2023504184A JP7850132B2 JP 7850132 B2 JP7850132 B2 JP 7850132B2 JP 2023504184 A JP2023504184 A JP 2023504184A JP 2023504184 A JP2023504184 A JP 2023504184A JP 7850132 B2 JP7850132 B2 JP 7850132B2
Authority
JP
Japan
Prior art keywords
ifn
patients
pharmaceutical composition
sars
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023504184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535710A5 (enExample
JP2023535710A (ja
Inventor
マースデン，リチャード
モンク，フィリップ
ウィルキンソン，トム
Original Assignee
シナーゲン リサーチ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2011216.5A external-priority patent/GB202011216D0/en
Priority claimed from GBGB2011284.3A external-priority patent/GB202011284D0/en
Priority claimed from GBGB2106014.0A external-priority patent/GB202106014D0/en
Application filed by シナーゲン リサーチ リミテッド filed Critical シナーゲン リサーチ リミテッド
Publication of JP2023535710A publication Critical patent/JP2023535710A/ja
Publication of JP2023535710A5 publication Critical patent/JP2023535710A5/ja
Application granted granted Critical
Publication of JP7850132B2 publication Critical patent/JP7850132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023504184A 2020-07-20 2021-07-19 ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ Active JP7850132B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2011216.5A GB202011216D0 (en) 2020-07-20 2020-07-20 Use of inhaled interferon-beta to improve outcome in sars-cov-2 infected patients
GB2011216.5 2020-07-20
GBGB2011284.3A GB202011284D0 (en) 2020-07-21 2020-07-21 Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients
GB2011284.3 2020-07-21
GB2106014.0 2021-04-27
GBGB2106014.0A GB202106014D0 (en) 2021-04-27 2021-04-27 Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients
PCT/GB2021/051853 WO2022018422A1 (en) 2020-07-20 2021-07-19 Inhaled interferon-beta for improving outcome in sars-cov-2 infected patients

Publications (3)

Publication Number Publication Date
JP2023535710A JP2023535710A (ja) 2023-08-21
JP2023535710A5 JP2023535710A5 (enExample) 2024-07-26
JP7850132B2 true JP7850132B2 (ja) 2026-04-22

Family

ID=77168292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504184A Active JP7850132B2 (ja) 2020-07-20 2021-07-19 ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ

Country Status (5)

Country Link
US (1) US20230338475A1 (enExample)
EP (1) EP4181944A1 (enExample)
JP (1) JP7850132B2 (enExample)
KR (1) KR20230041097A (enExample)
WO (1) WO2022018422A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022154542A1 (ko) * 2021-01-13 2022-07-21 에이비온 주식회사 잠재적인 호흡기바이러스 감염 개체에 인터페론-베타를 투여하는 것을 포함하는 호흡기바이러스에 대한 예방적 투여 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
CN1535724B (zh) 2003-04-23 2012-09-05 北京金迪克生物技术研究所 重组人干扰素在制备预防严重性急性呼吸道综合征的药物的用途
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
CN1927389B (zh) 2004-09-10 2012-11-14 北京金迪克生物技术研究所 含有人干扰素的药物组合物在制备预防或/和治疗呼吸道病毒感染疾病药物方面的应用
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
US9421243B2 (en) * 2010-03-12 2016-08-23 Synairgen Research Limited Therapy for influenza like illness
JP7642536B2 (ja) * 2018-11-15 2025-03-10 ブルーウィロー バイオロジクス、インコーポレイテッド 強化された透過性を有するナノエマルジョン組成物
CN115867288A (zh) * 2020-03-27 2023-03-28 维克多瑞有限公司 用于治疗呼吸系统病症的组合物
US20210299226A1 (en) * 2020-03-31 2021-09-30 Claresa Levetan Method of treating and preventing coronaviruses with low dosage interferon beta-1a as a th17 inhibitor

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Am. J. Respir. Crit. Care. Med.，2014年，vol.190, issue 2，p.145-154
Clinical evaluation of IFN beta1b in COVID-19 pneumonia: a retrospective study，medRxiv，2020年05月21日，https://doi.org/10.1101/2020.05.15.20084293
Efficacy and safety of interferon β-1a intreatment of severe COVID-19: A randomized clinical trial，medRxiv，2020年05月30日，https://doi.org/10.1101/2020.05.28.20116467
Nat. Commun.，2020年07月，vol.11, issue 1，3810, p.1-12
NCT04385095 Trial of Inhaled Anti-viral(SNG001) for SARS-CoV-2 (COVID-19) Infection，ClinicalTrials.gov，2020年05月11日，https://www.clinicaltrials.gov/study/NCT04385095?tab=history&a=1#version-content-panel>
Potent Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection，bioRxiv，2020年04月05日，https://doi.org/10.1101/2020.04.02.022764
Prof. Stephen Holgate，INFβ therapy forCOVID-19: the new SNG001 drug，HS Talks，2020年05月27日，https://hstalks.com/t/4301/inf-therapy-for-covid-19-the-new-sng001-drug/

Also Published As

Publication number Publication date
KR20230041097A (ko) 2023-03-23
EP4181944A1 (en) 2023-05-24
WO2022018422A1 (en) 2022-01-27
JP2023535710A (ja) 2023-08-21
US20230338475A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
Gavriatopoulou et al. Emerging treatment strategies for COVID-19 infection
Panahi et al. An overview on the treatments and prevention against COVID-19
JP2023526547A (ja) 気道粘膜におけるウイルス複製を低下させるための特定の薬物のシステム、方法、及び使用
US20230079150A1 (en) Methods for prevention or treatment of virus-induced organ injury or failure with il-22 dimer
Ohadian Moghadam A review on currently available potential therapeutic options for COVID-19
WO2021259195A1 (zh) 治疗新型冠状病毒肺炎的联合用药物
CN111346219A (zh) 干扰素在制备预防冠状病毒感染或预防冠状病毒感染引发的疾病的药物中的用途
JP2014501718A (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
WO2021207399A1 (en) Hydrolysable tannins for use in mitigating acute respiratory distress syndrome
JP2026077677A (ja) コロナウイルス感染症の処置のための方法
Kevadiya et al. Pharmacotherapeutics of SARS-CoV-2 infections
CN111671886B (zh) 一种预防高危易感人群感染冠状病毒或发生冠状病毒感染疾病的药物组合及其用途
WO2022056897A1 (zh) 白细胞介素37与干扰素联用在治疗病毒感染中的应用
JP2023535710A (ja) ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ
Mercuri et al. Priming mucosal pathogen-agnostic innate immunity with an intranasal TLR2/6 agonist in an aged population
Alihosseini et al. Current drugs with potential for coronavirus disease 2019 therapy: a literature review
EP2544705B1 (en) Interferon beta for use in the treatment of lower respiratory tract illness caused by influenza
CN116472054A (zh) 用于改善SARS-CoV-2感染患者的预后的吸入型干扰素-β
CN101365474B (zh) 用于治疗呼吸道疾病的干扰素λ疗法
JP2023535710A5 (enExample)
Simbirtsev Prospects for cytokine therapy in acute respiratory viral infections, including COVID-19
Elmenshawy et al. Different Therapeutic Modalities for management of COVID-19
Mtewa et al. SARS-CoV-2 vaccine development
Balef et al. A Recent Update on the Clinical Trials and Effectiveness of Drugs Used in COVID-19, MERS and SARS Coronaviruses
CN111228491B (zh) Ip-10抑制剂在预防和/或治疗寨卡病毒感染中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260324

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260410

R150 Certificate of patent or registration of utility model

Ref document number: 7850132

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150